Therapeutic cargo via polysaccharide coating

Therapeutic cargo via polysaccharide coating refers to a drug delivery strategy where active pharmaceutical ingredients are encapsulated or surface-modified with natural or synthetic polysaccharides such as hyaluronic acid, chitosan, or alginate (Source: PubMed, PMC6270504). This approach is designed to enhance the stability, biocompatibility, and pharmacological profile of the cargo, protecting it from premature degradation in the systemic circulation (Source: PubMed, PMC6163705). Polysaccharide coatings often provide functional benefits, such as mucoadhesion or active targeting to specific tissues; for instance, hyaluronic acid coatings are frequently used to target CD44-overexpressing tumor cells (Source: PubMed, PMC4754540). While highly versatile for treating various conditions including cancer and inflammation, this is a delivery modality rather than a discrete biological target like a receptor or enzyme (Source: PubMed, PMC7464854). The use of these coatings allows for controlled release and reduced systemic toxicity of potent drugs, though challenges remain regarding the standardization of polymer properties and potential immunogenic responses.

Other names

Polysaccharide-based drug delivery systemPolysaccharide-coated nanoparticlesGlycan-based nanocarriersPolysaccharide-encapsulated therapeutics

Polysaccharide coatings facilitate the delivery of therapeutic cargo by improving solubility, extending circulation time, and enabling targeted uptake through interactions with specific cell-surface receptors (e.g., CD44 for hyaluronic acid) or environmental triggers like pH changes (Source: PubMed, PMC6270504).